ORIG3N

develops treatments for rare genetically inherited diseases with a focus on heart, liver and neurodegenerative indications...
Read more
ORIG3N Co-Founder & CEO: Robin Y. Smith

Co-Founder & CEO

Robin Y. Smith

CEO Approval Rating

80/100

Est. Annual Revenue
$100K-5.0M
Agree?
Est. Employees
25-100
Agree?
Funding
$36M
Acquisitions
1

ORIG3N Competitors

1Ultragenyx
2Qrativ
3Sarepta
4BioMarin
5twoXAR
6Santhera
7Abeona
8BERG
9Clementia Pharmaceuticals, Inc.
10Adaptimmune

Trending Companies